Evidence map›Paper›PMID 39556165›Full record

ArticleInfection2025

In vitro activity of ceftazidime-avibactam/aztreonam combination against MBL-producing Pseudomonas aeruginosa strains.

Niklas Klein, Jonathan Jantsch, Michaela Simon, Jürgen Rödel, Sören L Becker, Annerose Serr, Joerg Steinmann, Stefan F Ehrentraut, Ernst Mollitor, Gunnar T R Hischebeth

Abstract read
PubMed Publisher
In one paragraph

Article in Infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Niklas KleinDepartment of Microbiology and Hospital Hygiene, Bundeswehr Central Hospital Koblenz, 56070, Koblenz, Germany. niklasklein@bundeswehr.org.
Jonathan JantschInstitute of Clinical Microbiology and Hygiene, Regensburg University Hospital, 93053, Regensburg, Germany.
Michaela SimonInstitute of Clinical Microbiology and Hygiene, Regensburg University Hospital, 93053, Regensburg, Germany.
Jürgen RödelInstitute of Medical Microbiology, Jena University Hospital, 07743, Jena, Germany.
Sören L BeckerInstitute of Medical Microbiology and Hygiene, Saarland University, 66421, Homburg, Germany.
Annerose SerrDepartment for Medical Microbiology and Hygiene, University Hospital Freiburg, 79104, Freiburg, Germany.
Joerg SteinmannInstitute of Clinical Hygiene, Medical Microbiology and Infectiology, Paracelsus Medical University, Klinikum Nürnberg, 90419, Nuremberg, Germany.
Stefan F EhrentrautDepartment of Anesthesiology and Intensive Care Medicine, University Hospital Bonn, 53127, Bonn, Germany.
Ernst MollitorInstitute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, 53127, Bonn, Germany.
Gunnar T R HischebethInstitute of Medical Microbiology, Immunology and Parasitology, University Hospital Bonn, 53127, Bonn, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe emergence of multidrug-resistant P. aeruginosa isolates poses a challenge to healthcare systems worldwide. Rising numbers in deaths, duration of hospitalization as well as failing treatments prove the hazards posed by these pathogens. This and the lack of promising therapeutic options highlight the urgency of antibiotic drug development. As interim solution or alternative to the development of new antibiotic drugs, investigation of novel combinations of existing antibiotic drugs can be an economic and swift approach. Therefore, this study addresses the evaluation of in vitro activity of the antibiotic combination of ceftazidime-avibactam/aztreonam against MBL-producing P. aeruginosa strains.

methodsWe tested 153 isolates from six university hospitals via microdilution against their susceptibility to meropenem, aztreonam, ceftazime-avibactam and the minimal inhibitory concentration of the combination of ceftazidime-avibactam/aztreonam. 64 isolates produced carbapenemases of which 61 were VIM-, 2 NDM- and 1 OXA-producer.

resultsWe were able to show that the synergetic effects of this regimen with an avibactam concentration of 4 mg/l and an aztreonam concentration of 16 mg/l could successfully lower the number of MBL-producing isolates that showed a high minimal inhibitory concentration compared to a carbapenemase-negative control group in vitro.

conclusionThe antibiotic combination consisting of ceftazidime-avibactam/aztreonam represents a possible approach to the treatment of patients infected with multidrug-resistant P. aeruginosa isolates.

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonambeta-LactamasesCeftazidimePseudomonas aeruginosaBacterial ProteinsDrug CombinationsDrug Resistance, Multiple, BacterialDrug SynergismHumansMicrobial Sensitivity TestsPseudomonas InfectionsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsAztreonamBacterial Proteinsbeta-LactamasesCeftazidimeDrug CombinationsAvibactamAztreonamCeftazidimeMBLMulti drug resistancePseudomonas aeruginosa

Identifiers

PMID39556165

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.